Every 8-K that Galectin Therapeutics Inc. (GALT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow GALT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GALT filings page.
Galectin Therapeutics Inc. reported a larger net loss for the three months ended June 30, 2026 while advancing its lead drug belapectin toward a registrational Phase 3 trial in MASH cirrhosis and portal hypertension. Net loss was $9.1 million versus $7.5 million a year earlier, with total operating expenses of $4.0 million, down from $4.6 million, reflecting lower research and development spending partly offset by higher general and administrative expenses.
Cash and cash equivalents were $13.3 million and total liabilities $151.7 million as of June 30, 2026, resulting in a stockholders’ deficit of $(138.6) million. Management highlighted an agreement with the FDA on key elements of the planned registrational Phase 3 belapectin trial and noted the recent issuance of common stock converting approximately $105.8 million of debt and accrued interest owed to the company’s chairman, which it stated significantly enhanced the capital structure.
Galectin Therapeutics Inc. converted approximately $105.8 million of debt owed to its chairman and largest stockholder, Richard E. Uihlein, into equity effective July 31, 2026. The conversion eliminated $91.0 million of principal and about $14.8 million of accrued interest arising from five line-of-credit facilities.
In exchange, the company issued 34,376,167 shares of common stock at a blended average conversion price of about $3.07 per share, using the Section 3(a)(9) exemption from registration. After the transaction, 100,849,644 common shares and 197,500 Series A Voting Preferred shares were outstanding, and Mr. Uihlein beneficially holds roughly 44.3% of voting power, or 49.3% including warrants. A separate $10 million supplemental credit facility from December 2025 remains undrawn and available, and the company is obligated to register the resale of the new shares within 180 days of conversion.
Galectin Therapeutics Inc. announced positive feedback from an in person FDA Type C meeting that supports advancing its lead drug belapectin into a Phase 3 trial for patients with MASH cirrhosis and portal hypertension. The company and FDA reached alignment on the overall study design, composite primary endpoint, and regulatory framework.
The Phase 3 trial is planned as a randomized, double-blind, placebo-controlled study using a single 2 mg dose of belapectin, focusing on preventing disease progression, including the development of large esophageal varices. FDA accepted Galectin’s blinded central endoscopy review methodology and confirmed that the proposed endpoints and structure are appropriate for a traditional full approval pathway.
Galectin plans to submit the final Phase 3 protocol in the third quarter of 2026 and is pursuing potential strategic and financial partners to support the program. Belapectin holds Fast Track designation and targets a high-risk patient group with substantial unmet medical need.
Galectin Therapeutics Inc. reported first-quarter 2026 results showing a smaller net loss while continuing to advance its belapectin program for MASH cirrhosis. For the three months ended March 31, 2026, net loss was $5.0 million compared with $9.6 million a year earlier, and basic and diluted net loss per share improved from $0.15 to $0.08.
Research and development expense declined to $2.2 million from $6.5 million, while general and administrative expense rose to $1.8 million from $1.4 million, leading to total operating expenses of $4.1 million versus $7.9 million. Cash and cash equivalents were $14.1 million as of March 31, 2026, down from $17.7 million at December 31, 2025, and stockholders’ deficit was $132.0 million.
Galectin Therapeutics Inc. reported full-year 2025 results showing a narrower loss while advancing its belapectin program for MASH cirrhosis and portal hypertension. Net loss was $30.8 million for 2025, improved from $47.0 million in 2024, as total operating expenses fell to $20.1 million from $42.4 million on sharply lower research and development spending.
Basic and diluted net loss per share improved to $0.48 from $0.76, with 63.9 million shares used in the 2025 per-share calculation. Cash and cash equivalents were $17.7 million at December 31, 2025, up from $15.1 million a year earlier, and the company highlighted an additional $10 million line of credit from its chairman, extending projected cash runway through April 2027.
Management emphasized encouraging biomarker and clinical signals from the NAVIGATE study supporting belapectin’s potential antifibrotic and disease‑modifying activity in MASH cirrhosis and portal hypertension. Multiple NAVIGATE abstracts, including an oral presentation, were accepted for the EASL Congress, and the company expects an FDA meeting in the second quarter of 2026 to discuss next steps for belapectin.
Galectin Therapeutics Inc. appointed Henry Brem, M.D. as an independent member of its Board of Directors, effective March 12, 2026. The company states he was not appointed under any arrangement with another person and has no related-party transactions requiring disclosure under Regulation S-K Item 404(a).
Dr. Brem is a renowned neurosurgeon-scientist and translational medicine leader, serving as the Henry Brem Professor of Neurosurgery at Johns Hopkins University and Co-Director of the Brain Cancer Program at the Sidney Kimmel Comprehensive Cancer Center. He helped develop image-guided neurosurgical techniques and localized drug delivery systems such as Gliadel wafers, has published more than 416 peer-reviewed papers, holds multiple patents, and has been continuously funded by the NIH for over four decades.
The Board believes his extensive medical, clinical development, and leadership background will support Galectin’s strategy as it advances its galectin-3 inhibitor belapectin for patients with MASH cirrhosis, portal hypertension, and certain cancers. He will receive compensation consistent with the company’s standard non-employee director program.
Galectin Therapeutics Inc. reported that its board of directors, following a recommendation from the compensation committee, approved cash retention bonuses for two senior executives. The Chief Medical Officer, Dr. Khurram Jamil, was granted a $300,000 cash retention bonus, and the Chief Financial Officer, Jack Callicutt, was granted a $150,000 cash retention bonus.
The bonuses will be paid in three equal installments on June 1, 2026, September 1, 2026 and December 1, 2026. Each officer must repay the full retention bonus if they voluntarily resign without good reason or are terminated for cause before December 31, 2026, consistent with their employment agreements. This structure is designed to encourage continuity in these key leadership roles through the end of 2026.
Galectin Therapeutics Inc. reported that Marc Rubin resigned from its Board of Directors effective January 10, 2026. The company states that his resignation is not due to any disagreement with Galectin on its operations, policies, or practices, indicating an orderly governance change rather than a dispute-driven departure.
Galectin Therapeutics Inc. reported the results of its 2025 Annual Meeting of Stockholders held on December 3, 2025. Stockholders elected all nominated directors to serve until the next annual meeting or until their successors are elected and qualified, with each nominee receiving more votes for than withheld.
Stockholders approved a non-binding advisory resolution on executive compensation, with 25,260,489 votes for, 639,415 against and 310,420 abstentions, alongside 19,513,532 broker non-votes. In a separate advisory vote on how often to hold future say-on-pay votes, 22,075,944 votes favored a three-year frequency, and the Board determined that advisory votes on named executive officer compensation will be held every three years. Stockholders also ratified the selection of Cherry Bekaert LLP as the company’s independent registered public accounting firm for the year ending December 31, 2025, with 45,458,024 votes for, 142,268 against and 123,564 abstentions.
Galectin Therapeutics Inc. filed an 8-K stating it furnished a press release with results of operations and financial condition for the nine months ended September 30, 2025, along with a business update. The information under Item 2.02 is furnished, not filed, and the press release is attached as Exhibit 99.1 dated November 14, 2025.
Galectin Therapeutics (GALT) reported that it presented results from its NAVIGATE trial at the AASLD 2025 Annual Meeting and posted an updated Corporate Presentation. The company also issued a press release; both materials were provided as Exhibits 99.1 and 99.2.
The materials were furnished under Item 7.01 of a Form 8-K and are not deemed filed under the Exchange Act. The disclosures include forward-looking statements subject to the cautionary notes in the exhibits and other SEC reports.
Galectin Therapeutics Inc. filed a current report to inform investors that it has posted an updated Corporate Presentation on its website, dated September 8, 2025. The presentation is furnished as Exhibit 99.1 and is incorporated by reference in the report, but is specifically described as “furnished” rather than “filed,” which limits certain legal liabilities under securities laws. The company also notes that the presentation and the report contain forward-looking statements that are subject to risks and uncertainties described in its other SEC reports.
Galectin Therapeutics Inc. furnished a Current Report on Form 8-K on August 14, 2025 announcing its results of operations and financial condition for the six months ended June 30, 2025 and providing a business update. The company incorporated by reference a press release dated August 14, 2025 filed as Exhibit 99.1 and included an interactive cover page XBRL as Exhibit 104. The filing notes that the press release contains forward-looking statements subject to risks described in Galectin's Annual Report for the year ended December 31, 2024. The information in Item 2.02 is furnished, not filed.